IL268138B - Combinations of cabozantinib and atezolizumab to treat cancer - Google Patents
Combinations of cabozantinib and atezolizumab to treat cancerInfo
- Publication number
- IL268138B IL268138B IL268138A IL26813819A IL268138B IL 268138 B IL268138 B IL 268138B IL 268138 A IL268138 A IL 268138A IL 26813819 A IL26813819 A IL 26813819A IL 268138 B IL268138 B IL 268138B
- Authority
- IL
- Israel
- Prior art keywords
- subjects
- compound
- cabozantinib
- atezolizumab
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448869P | 2017-01-20 | 2017-01-20 | |
| US201762458447P | 2017-02-13 | 2017-02-13 | |
| PCT/US2018/014523 WO2018136796A1 (en) | 2017-01-20 | 2018-01-19 | Combinations of cabozantinib and atezolizumab to treat cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL268138A IL268138A (en) | 2019-09-26 |
| IL268138B true IL268138B (en) | 2022-08-01 |
Family
ID=61569414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268138A IL268138B (en) | 2017-01-20 | 2018-01-19 | Combinations of cabozantinib and atezolizumab to treat cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11198731B2 (enExample) |
| EP (1) | EP3570840B1 (enExample) |
| JP (3) | JP7222895B2 (enExample) |
| KR (2) | KR102610764B1 (enExample) |
| CN (4) | CN110352057A (enExample) |
| AU (2) | AU2018210397B2 (enExample) |
| BR (1) | BR112019015011A2 (enExample) |
| CA (1) | CA3049452A1 (enExample) |
| ES (1) | ES3031468T3 (enExample) |
| IL (1) | IL268138B (enExample) |
| MA (1) | MA47310A (enExample) |
| MX (2) | MX389966B (enExample) |
| UA (1) | UA126970C2 (enExample) |
| WO (1) | WO2018136796A1 (enExample) |
| ZA (1) | ZA201904652B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136796A1 (en) * | 2017-01-20 | 2018-07-26 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| SG11202006921PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| JP7653352B2 (ja) * | 2018-09-05 | 2025-03-28 | エクスプレステック、リミテッド、ライアビリティ、カンパニー | 免疫グロブリンａ製剤 |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| US20230301979A1 (en) * | 2020-07-31 | 2023-09-28 | Exelixis, Inc. | Combinations for the treatment of cancer |
| US20230314440A1 (en) * | 2020-08-21 | 2023-10-05 | Exelixis, Inc. | Method of treating cancer |
| EP4308243A4 (en) * | 2021-03-19 | 2025-02-26 | Merck Sharp & Dohme LLC | METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES |
| US11620580B2 (en) * | 2021-04-01 | 2023-04-04 | Banjo Health Inc. | Methods and systems for probabilistic filtering of candidate intervention representations |
| CN120417903A (zh) | 2023-01-31 | 2025-08-01 | 汉达癌症医药责任有限公司 | 改良的卡博替尼组合物及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| DK2387563T4 (da) * | 2009-01-16 | 2022-07-18 | Exelixis Inc | Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer |
| EP2593090B1 (en) | 2010-07-16 | 2021-10-13 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| BR112015025408A8 (pt) * | 2013-04-04 | 2018-07-10 | Exelixis Inc | combinações de drogas para tratar câncer |
| MX384828B (es) * | 2014-02-14 | 2025-03-14 | Exelixis Inc | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. |
| CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| EP3445361A1 (en) * | 2016-04-19 | 2019-02-27 | Exelixis, Inc. | Triple negative breast cancer treatment method |
| WO2018136796A1 (en) * | 2017-01-20 | 2018-07-26 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
-
2018
- 2018-01-19 WO PCT/US2018/014523 patent/WO2018136796A1/en not_active Ceased
- 2018-01-19 AU AU2018210397A patent/AU2018210397B2/en active Active
- 2018-01-19 CN CN201880013200.7A patent/CN110352057A/zh active Pending
- 2018-01-19 KR KR1020197024015A patent/KR102610764B1/ko active Active
- 2018-01-19 CN CN202311144073.3A patent/CN117205312A/zh active Pending
- 2018-01-19 KR KR1020237041680A patent/KR20230169458A/ko not_active Ceased
- 2018-01-19 CN CN202311144084.1A patent/CN117771363A/zh active Pending
- 2018-01-19 JP JP2019539223A patent/JP7222895B2/ja active Active
- 2018-01-19 ES ES18709192T patent/ES3031468T3/es active Active
- 2018-01-19 EP EP18709192.1A patent/EP3570840B1/en active Active
- 2018-01-19 US US16/479,143 patent/US11198731B2/en active Active
- 2018-01-19 MA MA047310A patent/MA47310A/fr unknown
- 2018-01-19 CA CA3049452A patent/CA3049452A1/en active Pending
- 2018-01-19 CN CN202311144074.8A patent/CN117205313A/zh active Pending
- 2018-01-19 IL IL268138A patent/IL268138B/en unknown
- 2018-01-19 UA UAA201909420A patent/UA126970C2/uk unknown
- 2018-01-19 MX MX2019008032A patent/MX389966B/es unknown
- 2018-01-19 BR BR112019015011A patent/BR112019015011A2/pt not_active Application Discontinuation
-
2019
- 2019-07-03 MX MX2022001718A patent/MX2022001718A/es unknown
- 2019-07-16 ZA ZA2019/04652A patent/ZA201904652B/en unknown
-
2021
- 2021-11-04 US US17/519,327 patent/US20220056138A1/en not_active Abandoned
-
2022
- 2022-06-29 JP JP2022104523A patent/JP2022121594A/ja active Pending
-
2023
- 2023-12-28 JP JP2023222710A patent/JP2024019720A/ja active Pending
-
2024
- 2024-05-24 AU AU2024203472A patent/AU2024203472A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX389966B (es) | 2025-03-20 |
| CN117771363A (zh) | 2024-03-29 |
| WO2018136796A1 (en) | 2018-07-26 |
| CN117205313A (zh) | 2023-12-12 |
| MX2022001718A (es) | 2022-03-11 |
| KR20190107103A (ko) | 2019-09-18 |
| ES3031468T3 (en) | 2025-07-09 |
| US20190352403A1 (en) | 2019-11-21 |
| JP7222895B2 (ja) | 2023-02-15 |
| US20220056138A1 (en) | 2022-02-24 |
| BR112019015011A2 (pt) | 2020-04-28 |
| MA47310A (fr) | 2019-11-27 |
| KR102610764B1 (ko) | 2023-12-07 |
| JP2024019720A (ja) | 2024-02-09 |
| IL268138A (en) | 2019-09-26 |
| AU2024203472A1 (en) | 2024-06-13 |
| MX2019008032A (es) | 2019-12-16 |
| ZA201904652B (en) | 2024-11-27 |
| CA3049452A1 (en) | 2018-07-26 |
| UA126970C2 (uk) | 2023-03-01 |
| CN110352057A (zh) | 2019-10-18 |
| KR20230169458A (ko) | 2023-12-15 |
| AU2018210397A1 (en) | 2019-07-25 |
| US11198731B2 (en) | 2021-12-14 |
| NZ755494A (en) | 2025-06-27 |
| JP2022121594A (ja) | 2022-08-19 |
| AU2018210397B2 (en) | 2024-02-29 |
| CN117205312A (zh) | 2023-12-12 |
| EP3570840B1 (en) | 2025-03-19 |
| EP3570840A1 (en) | 2019-11-27 |
| JP2020514311A (ja) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11198731B2 (en) | Combinations of cabozantinib and atezolizumab to treat cancer | |
| Marra et al. | Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment | |
| CN110536684A (zh) | 三联组合制剂以及治疗心血管疾病或降低心血管疾病风险的方法 | |
| US20220409620A1 (en) | Reducing immunogenicity to pegloticase | |
| TW202034955A (zh) | 使用免疫調節治療癌症之新穎方法 | |
| HK40018507A (en) | Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer | |
| HK40018507B (en) | Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer | |
| NZ795674A (en) | Combinations of cabozantinib and atezolizumab to treat cancer | |
| TW202320790A (zh) | 治療癌症之方法 | |
| TW202237078A (zh) | 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物 | |
| Schultze-Seemann et al. | Bevacizumab plus IFN-alpha-2a in first-line treatment of patients with advanced or metastatic renal cell carcinoma: A prospective german non-interventional study | |
| EA041548B1 (ru) | Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей | |
| HK40016051A (en) | Combinations of cabozantinib and atezolizumab to treat cancer | |
| Zeng et al. | Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study | |
| Zhang et al. | Efficacy and safety of HIPEC combined with PD-1 and SOX chemotherapy for gastric or oesophagogastric junctional cancer with peritoneal metastasis (HISTORIA): protocol for a prospective, multicentre, single-arm, phase II study | |
| Dagogo-Jack et al. | Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study | |
| Carthon | Winship Protocol#: Winship4643-19 TITLE: A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma | |
| DEVELOPM | Drug DeveloPment | |
| Liu et al. | A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects | |
| Heist | Phase II trial of cabozantinib (XL184) in patients with advanced solid (non-breast | |
| Ying | Efficacy and safety of sintilimab and anlotinib in combination with gemcitabine plus cisplatin as first-line therapy in patients with advanced biliary tract cancer: a randomized, open-label, multicentre, phase 2 SAGC study | |
| Niemann et al. | EUDRACT NUMBER: Clinicaltrials. gov number | |
| Wei | A Phase II, Single-center, Single-arm Clinical Trial on the Efficacy and Safety of Anti-PD-1 antibody (IBI308) Combined with Anlotinib for the Treatment of Recurrent or Advanced Endometrial Cancer | |
| Person | Study protocol | |
| Climent | Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients: CABOMAYOR study |